Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines, Monte Rosa uses SEC reports to describe its clinical programs, collaborations, and financial condition.
Among the most informative documents for GLUE are current reports on Form 8-K, which the company uses to announce material events such as interim clinical data, financial results, and collaboration updates. For example, Monte Rosa has furnished 8-Ks summarizing positive interim Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and reporting quarterly financial results and business updates, including progress on MRT-8102, MRT-6160, and its partnerships with Novartis and Roche.
Investors can also reference Monte Rosa’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which the company cites in its forward-looking statements as sources of detailed risk factors and operational information. These periodic filings typically include descriptions of the QuEEN™ discovery engine, the status of key programs such as MRT-8102, MRT-2359, and MRT-6160, and the structure of collaboration and license agreements.
On Stock Titan, GLUE filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools help summarize lengthy documents, highlight key sections on clinical development, collaboration revenue, and cash runway, and make it easier to locate items on topics such as interim trial results, planned Phase 2 studies, or changes in capital structure. Users can quickly review Form 8-K disclosures about material events alongside the underlying press releases and presentations referenced in those filings.
Monte Rosa Therapeutics (GLUE) furnished an update on operations, announcing it has reported financial results for the quarter ended September 30, 2025. The full details are contained in a press release furnished as Exhibit 99.1.
The company also posted a revised corporate presentation to the Presentations section of its website on November 6, 2025. Information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liability or incorporated by reference unless expressly stated.
Monte Rosa Therapeutics, Inc. received a joint Schedule 13G filing showing that Dimension Capital I, L.P. and affiliated reporting persons collectively beneficially hold 4,757,563 shares of the issuer's common stock, representing 7.7% of the class. The filing lists the reporting persons as Dimension Management, L.P., Dimension Capital I GP, LLC, Dimension Management GP, LLC, Dimension Capital I, L.P. and individuals Adam Goulburn, Zavain Dar, and Nan Li. The cover information states the ownership percentages are calculated using 61,759,350 outstanding shares reported by the issuer as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the disclosed shares and certify the shares were not acquired to change control of the company.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 3,725,000 shares of Monte Rosa Therapeutics common stock, representing 6.1% of the class. The reporting persons state they have sole voting and sole dispositive power over these shares and that the shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The percentage is calculated using 61,509,821 shares outstanding as of May 5, 2025, per the company's quarterly report. The filing includes a certification that the securities were acquired in the ordinary course of business and were not acquired to change or influence control; signatures appear for Avoro and for Behzad Aghazadeh.